Daily Health Insight: July 2013

Wednesday, July 31, 2013

One in five kids may outgrow asthma

One in five kids may outgrow asthma
As many as one in five youngsters with asthma may grow out of the respiratory condition as they age, new research indicates.

Tuesday, July 30, 2013

i2i’s Knowledge on Demand Analytics Platform Helps Health Care...

New package of solutions is focused on delivering intelligence -- beyond just technology -- for organizations in an ever-evolving health care delivery system.

(PRWeb July 30, 2013)

Read the full story at http://www.prweb.com/releases/2013/7/prweb10969956.htm

Conservative guidelines for back pain disregarded

Despite guidelines to treat back pain conservatively, the proportion of people prescribed powerful painkillers or referred for surgery has increased, according to a new study. Continue reading...

How to Reduce Extra Belly Fat for Women

Weight loss programs are not always meant to have a zero figure. Maintaining an effective body weight is essential to avoid embarrassment in addition to prevent several health conditions. Women may gain excess stomach fat ... For full post, click here.

CirrusMD Launches Mobile Physician Access Service

Mobile Physician Access. (PRNewsFoto/CirrusMD Inc.)

DENVER, Colo., July 30, 2013 /PRNewswire-iReach/ -- CirrusMD Inc. (www.CirrusMD.com) announced today that it has launched its secure healthcare communications platform with medical practices in the greater Boston and Sacramento regions. CirrusMD allows physicians to offer their patients video chat and direct messaging through a secure, cloud-based patient profile accessible over mobile devices and the Internet. The Company's goal is to bring the best in mobile communications to the doctor/patient relationship.

(Photo: http://photos.prnewswire.com/prnh/20130730/MN55193)

Co-founder Blake McKinney, MD, who is an ER doctor, originated the idea for CirrusMD after seeing patients waiting for hours on end in the emergency room for issues that their primary care doctors could easily manage, if accessible. He set out to create a service that provides patients with an easier means of accessing healthcare services, regardless of insurance status. The Company's services are designed to streamline practice productivity and transform industry business models, while also substantially reducing costs.

CirrusMD's first two launch partners are pioneers in introducing remote access and mass-market telemedicine into the context of their existing practices. Family Medicine Associates in Middleton, MA and Roseville Internal Medicine in Roseville, CA are the first providers to offer CirrusMD. According to Mark Allara, MD of Family Medicine Associates, "CirrusMD will help us change the way that we deliver medicine and interact with our patients." William Webster, MD of Roseville Internal Medicine says, "It is exciting to partner with CirrusMD in order to offer technology that brings value to both patients and our practice."

About CirrusMD Inc.

CirrusMD Inc. is a healthcare communications company focused on mobile physician access solutions. The Company offers a HIPAA compliant platform that allows medical practices and health systems to offer video chat and direct messaging to their patients over mobile devices and the Internet. CirrusMD is currently live with practices in Sacramento and Boston and is actively adding new partners. The Company is engaged in business development opportunities with major health systems, insurance companies, HMOs, ACOs, government payer programs, and corporate health and wellness plans. CirrusMD was founded in 2012 and has operations in Denver and Sacramento. For more information about CirrusMD, visit www.CirrusMD.com, or email info@CirrusMD.com.

Media Contact: Andrew Altorfer, CirrusMD Inc., 1-800-449-4512, info@cirrusmd.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE CirrusMD Inc.

Researchers aim to create virtual speech therapist

Researchers aim to create virtual speech therapist
PHILADELPHIA (AP) — Debi Green is trying to book a vacation, but she's having a hard time getting the words out. Even though it's been nearly nine years since she suffered a stroke, language sometimes fails her.

Comprehensive Care Corporation Signs Agreement With A National Leader In Pharmacy Benefit Management

TAMPA, Fla., July 30, 2013 /PRNewswire/ -- Comprehensive Care Corporation (OTC BB: CHCR), ("CompCare" or the "Company"), a leading behavioral health, substance abuse and pharmacy management provider for employers, Taft-Hartley health and welfare funds, managed care companies, third party administrators, and union–sponsored benefit plans, today announced the signing of an agreement with one of the nation's leading pharmacy benefit managers ("PBM"). The signing of this agreement completes the structure needed by CompCare to initiate the national launch of its Pharmacy Value Management Program ("PVM Program"). The PVM Program, constructed by CompCare over the last two years, is designed to save clients approximately 10% or more on their annual pharmacy spend by providing them with a pharmacy management price that is 10% less than their prior year's spend – fully secured by a performance bond.

Ramon Martinez, President of CompCare Pharmacy Solutions, Inc., said, "CompCare has placed all of the major components in the right order and is moving ahead with the initiation of the PVM Program. We believe that we will use our innovative Fourth Party Pharmacy Value Network (4PVN^TM) to change and improve the delivery of pharmacy benefit management while providing greater value and helping our clients decrease their costs in pharmacy spending."

In January of this year, CompCare announced the signing of its agreement with a leading, national surety bond provider giving CompCare the ability to "…back its new 'at-risk' Pharmacy Cost-Savings Program with fully guaranteed performance bonds." (See CompCare's release of January 8, 2013.) In March of this year, CompCare announced the signing of an agreement with Blasters, Drillers & Miners Union, Local No. 29, Laborers' International Union of North America (LIUNA), which agreement provided, in part, for CompCare to make its PVM Program available to Local 29 and guarantee "…Local 29 a minimum of a 10% savings and backed up its guarantee with a full performance bond issued by a nationally well-known and respected surety company." (See CompCare's release of March 19, 2013.) In May of this year, CompCare announced the signing of a pharmacy management savings agreement with Utica City School District. The agreement provides, in part, for CompCare to make its PVM Program available to Utica City School District and "…guarantee them a savings of at least 10% over their current pharmacy expense." (See CompCare's release of May 13, 2013.)

In June of this year, the Company announced that under the leadership of Lt. Colonel Ramon Martinez (USAF, Ret.), President of CompCare Pharmacy Solutions, Inc. (a wholly-owned subsidiary of the Company), CompCare had successfully retained the services of core salespeople "…needed to head up national sales force to sell our PVM Program." (See CompCare's release of June 10, 2013.) The Company currently has on retainer the services of three full-time salespeople and five additional commission-only salespeople located throughout the U.S. and Puerto Rico whose sole product is the PVM Program. The target markets of the PVM Program range from self-insured employer groups to Taft-Hartley health and welfare funds, as well as managed care companies.

Simultaneously with the above activities, the Company continued to actively engage in discussions and negotiations with various PBM's in order to broaden its capabilities to provide its clients with the promised savings. As a 4PVN^TM service provider, CompCare orchestrates and contracts for the delivery to the Participating Groups of agreed upon services, a complex network of "best of breed" PBM service providers.

CompCare believes that the signing of its latest PBM Agreement completes the development of its 4PVN^TM, positioning CompCare to offer its clients, and potential clients, the right PBM to service the client's membership through CompCare and make possible the guaranteed savings.

As a result of the signing of this agreement, the implementation procedure needed to initiate Local 29's new pharmacy program by year end has already commenced. The Company anticipates commencing implementation of similar union and/or municipality programs during Q3 and Q4 of this year.

The U.S. pharmacy benefit market has an annual prescription drug spend of approximately $325 billion. Management believes that given the uniqueness of its program, the quality of its sales force and its ability to attract clients by guaranteeing its performance at substantial savings off their prior year's drug spend, it will be able to penetrate a reasonable segment of the overall market within the next 24 months.

About Comprehensive Care Corporation

Established in 1969, CompCare provides behavioral health, substance abuse and pharmacy management services for employers, Taft-Hartley health and welfare Funds, managed care companies, third party administrators, and union–sponsored benefit plans throughout the United States. Headquartered in Tampa, Florida, CompCare focuses on personalized attention, flexibility, a commitment to high-quality services and innovative approaches that address both the specific needs of clients and changing healthcare industry demands. For more information, please call 813-288-4808 or visit our website at www.compcare.com

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond CompCare's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, the impact that the sales and business development team will have on the acceptance and adoption of CompCare's service offerings; the ability of CompCare to launch its pharmacy value management program for Local 29 in September 2013 and for Utica City School District shortly thereafter; the ability of CompCare to maximize its market share with new pharmacy initiatives, the ability of CompCare's new pharmacy cost-savings program to guarantee a 10% or more reduction in pharmacy costs, the ability of CompCare's pharmacy program to promote greater medication adherence without restricting access to needed medications, the ability of CompCare's pharmacy cost-savings program to change and improve the delivery of pharmacy benefit management, CompCare's ability to provide superior patient care while increasing its business and margins as a result of implementing its pharmacy cost-savings program, the ability to obtain a performance bond on satisfactory terms, the ability of CompCare and its staff to successfully execute its business plan, the ability of CompCare to offer and sell any of its products at a profit, changes in local, regional, and national economic and political conditions, the effect of governmental regulation, competitive market conditions, varying trends in member pharmacy utilization, our ability to manage healthcare operating expenses, our ability to achieve expected results from new business, the profitability, if any, from capitated pharmacy contracts or other products, increases or variations in cost of care, seasonality, CompCare's ability to obtain additional financing, and additional risk factors as discussed in the reports filed by the company with the Securities and Exchange Commission, which are available on its website at www.sec.gov. Any forward- looking statement in this release speaks only as of the date on which it is made. CompCare assumes no obligation to update or revise any forward-looking statements.

Investor Contacts:
Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940.262.3584

SOURCE Comprehensive Care Corporation

Monday, July 29, 2013

Your Fitness Success Begins With Your Belief

Your beliefs around being successful in your fitness goals may be holding you back. Where did they come from? What are they? How can you change them? Continue reading...

Healthy Monday Tip: Drink Guilt-Free, Skinny Coffee

coffee If you're not a coffee drinker, today's blog post may not apply to you....unless you read news headlines. This morning, I saw several news stories that made me think that my morning java had magical lifesaving powers. Almost every news agency was reporting a link between coffee and a decreased risk of suicide. As it turns out, drinking coffee can't really save your life, but it did give coffee drinkers, like me, one more reason not to give up my habit.

...

Read Full Post

Here is the full post.

Time to Buy Diet Pills and Shed Extra Pounds

You must have heard people discussing about their diet regimes many times because it is one of the most common things which is being followed by numbers of people to melt their extra pounds. It is the ideal way to get your body in shape within short period of time.

Transplants benefit obese kidney patients

Transplants benefit obese kidney patients
Researchers found that the risk of an obese person dying during the year after a kidney transplant dropped about 66%, compared to obese people who remained on dialysis.

Sunday, July 28, 2013

Eisai ottiene il parere positivo del CHMP ema per Zonegran® (zonisamide) ad uso pediatrico

HATFIELD, Regno Unito, July 29, 2013 /PRNewswire/ --

In data odierna Eisai rende noto che il Comitato dei Medicinali per Uso Umano (CHMP) dell'Agenzia Europea per i medicinali ha emesso parere favorevole all'uso di Zonegran^® (zonisamide) come terapia aggiuntiva nel trattamento delle persone con epilessia, di età pari o superiore a 6 anni, con crisi parziali (la forma più comune di epilessia) con o senza generalizzazione secondaria, in mono somministrazione giornaliera.^[1] Zonisamide è un farmaco antiepilettico (FAE) di seconda generazione dotato di un meccanismo d'azione multiplo e di una struttura chimica non correlata a quella di altri FAE.^[2] Attualmente zonisamide è indicato come terapia aggiuntiva nel trattamento delle crisi epilettiche a esordio parziale nelle persone adulte con epilessia e, a partire dal mese di luglio 2012, il farmaco può essere prescritto come monoterapia nelle persone adulte con epilessia con crisi parziali, con o senza generalizzazione secondaria, di nuova diagnosi.^[²^]

L'epilessia è un disturbo frequente nei bambini e la forma con crisi a esordio parziale è quella più comunemente osservata.^[3]^,^[4] Il numero stimato di bambini e adolescenti in Europa con epilessia attiva è pari a 0,9 milioni.^[5] Solo due terzi dei bambini e adolescenti affetti da epilessia raggiungono il controllo delle crisi una volta ricevuta l'idonea terapia FAE (farmaci antiepilettici) e molti di loro necessitano di farmaci antiepilettici aggiuntivi per migliorare tale controllo.^[6] Nei minori l'epilessia genera spesso gravi difficoltà per quanto riguarda apprendimento e problemi comportamentali, probabili cause di scarso rendimento scolastico. I problemi comportamentali associati all'epilessia includono iperattività, aggressività, tratti autistici, depressione e bassa autostima.^[7]

Nel commentare il parere positivo del CHMP, il Prof. Helen Cross, consulente onorario in Neurologia pediatrica al Great Ormond Street Hospital, ha dichiarato: "Esiste ancora un gran numero di minori affetti da epilessia che non raggiunge il controllo delle crisi e per i quali potrebbe quindi essere necessario più di un farmaco antiepilettico, per cercare di ridurre tali crisi. Nei minori con epilessia ad insorgenza precoce, migliorare il controllo delle crisi è di vitale importanza per la salute e lo sviluppo psicofisico. Ogni nuova opzione terapica è auspicabile e auspicata da parte dei medici specializzati in questo campo."

La proposta di estendere l'uso di zonisamide ai minori di età pari o superiore ai sei anni è basata sui dati dello studio di fase III CATZ, in doppio cieco, randomizzato, multicentrico, controllato con placebo, il quale ha dimostrato che la zonisamide è più efficace del placebo, ed è ben tollerata in pazienti affetti da epilessia pediatrica (6-17 anni) con crisi a esordio parziale trattati con uno o due farmaci antiepilettici aggiuntivi.^[^8]

In particolare, i risultati hanno mostrato che un numero significativamente maggiore di pazienti ha risposto positivamente al trattamento con zonisamide (50,0%, con > 50% di riduzione della frequenza delle crisi) rispetto al trattamento con placebo (31,0%).^[⁸^]

"Come società farmaceutica basata sulla ricerca, con un'attenzione particolare verso l'epilessia, ci siamo impegnati non solo a portare sul mercato nuove terapie innovative, ma anche a garantire i massimi benefici clinici dei nostri prodotti attualmente in commercio", ha dichiarato Patrick Standen, EMEA Brand Director, Eisai Europe Ltd. "Se approvata in Europa come terapia per i minori dai sei anni di età, la zonisamide offrirà ai giovani affetti da epilessia una nuova opzione che contribuirà a migliorare il loro controllo delle crisi".

Il continuo sviluppo di zonisamide rinforza la missione di Eisai di fornire assistenza sanitaria umana (hhc, human health care), l'impegno dell'azienda nella scoperta di soluzioni innovative per la prevenzione, la terapia e la cura delle malattie e per la salute e il benessere delle persone in tutto il mondo. Eisai è impegnata nell'area terapeutica dell'epilessia e a rispondere ai bisogni terapeutici non soddisfatti delle persone con epilessia e dei loro familiari. Eisai è orgogliosa del ruolo che detiene attualmente nel commercio dei prodotti per l'epilessia nella zona EMEA (Europa, Medio Oriente e Africa), superiore a qualsiasi altra azienda, e il suo impegno è quello di diventare l'azienda principale in Europa nel settore dell'epilessia entro il 2015, come previsto nel suo programma di sviluppo denominato Hayabusa.

Note per gli Editori

Informazioni su Zonegran (zonisamide) Zonisamide è autorizzata in Europa come monoterapia* nel trattamento delle crisi a esordio parziale, con o senza generalizzazione secondaria, nelle persone adulte con epilessia di nuova diagnosi. Inoltre, zonisamide è indicata come terapia aggiuntiva nel trattamento delle crisi a esordio parziale (con o senza generalizzazione secondaria) nelle persone adulte con epilessia. Possiede un meccanismo d'azione multiplo e non ha effetti apprezzabili sulle concentrazioni plasmatiche, allo steady state, degli altri farmaci antiepilettici, come fenitoina, carbamazepina e valproato.^[²^] Zonegran è uno dei soli quattro FAE con un comprovato livello A di efficacia in monoterapia di prima diagnosi per le persone adulte con epilessia con crisi ad esordio parziale.^[9]

Zonisamide è disponibile in capsule da 25mg, 50mg e 100mg. La dose giornaliera raccomandata per l'utilizzo in monoterapia è 100 mg una volta al giorno. Nella terza e quarta settimana la dose può essere aumentata a 200 mg al giorno fino a 300 mg al giorno nelle successive due settimane. La dose giornaliera iniziale raccomandata per l'uso combinato è di 50 mg in due dosi separate. Dopo una settimana la dose può essere aumentata a 100 mg al giorno e successivamente la dose può essere aumentata a intervalli settimanali, con incrementi fino a 100 mg.^[²^]

Per ulteriori informazioni visitare il sito web: http://www.eisai.co.uk

Studio 312 di Fase III (CATZ)^[8^]

Lo studio 312 è uno studio in doppio cieco, randomizzato, controllato con placebo, multicentrico (n = 207) per valutare l'efficacia e la sicurezza di zonisamide come terapia aggiuntiva nelle crisi parziali di pazienti pediatrici (6-17 anni). Nello studio, i minori affetti da epilessia parziale che ricevono uno o due farmaci antiepilettici sono stati randomizzati a ricevere zonisamide come farmaco aggiuntivo o placebo. Zonisamide è stato inizialmente somministrato a 1 mg/kg/die, fino alla dose bersaglio di 8 mg/kg/die fino a otto settimane (dosaggio a scalare consentito) e mantenuto per 12 settimane. L'endpoint primario di efficacia dello studio era la percentuale di responder (definito come una riduzione ≥ 50% di frequenza delle crisi rispetto al punto di riferimento iniziale) nel periodo di mantenimento di 12 settimane.

Le percentuali di risposta sono risultate essere il 50% per zonisamide rispetto al 31% per il placebo (p = 0.0044). L'incidenza complessiva degli eventi avversi derivanti dal trattamento (TEAE) era simile per zonisamide (55,1%) rispetto al placebo (50,0%), con bassi tassi di gravi TEAE in entrambi i bracci dello studio (3,7% zonisamide vs 2,0% placebo) e conseguente ritiro (0,9% vs 3,0%).

I risultati dello studio di fase III sono stati pubblicati nel luglio 2013 in Epilepsia^®.

Informazioni sull'epilessia

L'epilessia è una delle condizioni neurologiche più comuni al mondo, che colpisce circa 8 su 1000 persone in Europa.^[10]

Esistono 6 milioni di persone che convivono con l'epilessia in Europa e 50 milioni di persone al mondo.

L'epilessia è caratterizzata da un scarica anomala di impulsi delle cellule nervose nel cervello che causa la comparsa di crisi epilettiche. A seconda del tipo, le crisi possono essere limitate a una parte del corpo o possono essere generalizzate e coinvolgere l'intero corpo.

Le persone con epilessia possono provare sensazioni anomale, alterazioni del comportamento o della coscienza. L'epilessia è un disordine neurologico con molte possibili cause. Spesso la causa dell'epilessia è sconosciuta. Qualsiasi elemento di disturbo del normale schema dell' attività neuronale, dalla malattia al danno celebrale e ai tumori, può causare la comparsa di crisi epilettiche.

Informazioni su Eisai Europa nel campo dell'epilessia:

Eisai è impegnata nello sviluppo e nell'offerta di nuovi trattamenti per migliorare la qualità di vita delle persone con epilessia. Lo sviluppo dei FAE rappresenta un'area strategica per Eisai in Europa, il Medio Oriente, l'Africa, la Russia e l'Oceania (EMEA).

Nella regione EMEA Eisai dispone attualmente di quattro farmaci autorizzati alla commercializzazione nelle seguenti indicazioni terapeutiche:

Zonegran^® (zonisamide) come monoterapia^* e terapia aggiuntiva nei pazienti adulti con crisi a esordio parziale, con o senza generalizzazione secondaria. (Zonegran è in licenza dal produttore Dainippon Sumitomo Pharma).
Zebinix^® (eslicarbazepina acetato) ** come terapia aggiuntiva nel trattamento di pazienti adulti con crisi parziali, con o senza generalizzazione secondaria (Zebinix è sotto licenza di BIAL). Zebinix non è approvato da Swissmedic.
Inovelon^® (rufinamide, orphan drug)** come terapia aggiuntiva nel trattamento di crisi epilettiche associate alla sindrome di Lennox-Gastaut in pazienti di età pari o superiore a 4 anni.
Fycompa^® (perampanel) come terapia aggiuntiva** nel trattamento di crisi a esordio parziale, con o senza generalizzazione secondaria, in pazienti con epilessia di età pari o superiore a 12 anni.

* la monoterapia con Zonegran® non è attualmente rimborsata in Italia

** Zebinix® non è attualmente commercializzato in Italia

*** La sospensione di rufinamide non è attualmente in commercio in Italia

**** Fycompa® non è attualmente autorizzato in Italia

Informazioni su Eisai

Eisai è una casa farmaceutica leader a livello mondiale nel settore Ricerca e Sviluppo (R&S) e delinea come missione aziendale l'impegno di "dare priorità ai pazienti e alle famiglie e incrementare i benefici per la salute" definita da Eisai stessa "human health care" (hhc).

Eisai si concentra nelle sue attività di R&S in tre importanti aree terapeutiche:

Neuroscienze: morbo di Alzheimer, epilessia, dolore e perdita di peso
Oncologia: terapie antitumorali, regressione del tumore, estirpazione del tumore, anticorpi.
Reazioni immunologiche/vascolari: trombocitopenia, artrite reumatoide, psoriasi, malattie infiammatorie intestinali

Con attività negli Stati Uniti, in Asia, in Europa e nel mercato nazionale Giapponese, Eisai impiega oltre 10.000 dipendenti in tutto il mondo. Dal suo Knowledge Centre situato a Hatfield, Regno Unito, Eisai ha recentemente ampliato le proprie attività di business per includere l'Europa, il Medio Oriente, l'Africa, la Russia e l'Oceania (EMEA). Eisai EMEA è impegnata in operazioni di produzione vendita e marketing in oltre 20 mercati, tra cui Regno Unito, Francia, Germania, Italia, Spagna, Svizzera, Svezia, Irlanda, Austria, Danimarca, Finlandia, Norvegia, Portogallo, Repubblica Ceca, Slovacchia, Paesi Bassi, Belgio e Medio Oriente.

Per ulteriori informazioni visitare il sito Web http://www.eisai.co.uk

Bibliografia

1. Opinion of the Committee for Medicinal Products for Human use on a type II variation to the terms of the marketing authorsation for Zonegran, European Medicines Agency 2013

2. Eisai Ltd 2013. Zonegran Summary of Product Characteristics [ http://emc.medicines.org.uk ]

3. Berg AT, Shinnar S, Levy SR, Testa FM. Newly diagnosed epilepsy in children: presentation at diagnosis. Epilepsia 1999;40:445‒452.

4. Bergin AM. Pharmacotherapy of paediatric epilepsy. Expert Opin Pharmacother 2003;4:421‒431.

5. Forsgren L. et al. The epidemiology of epilepsy in Europe - a systematic review. European Journal of Neurology.2005 12(4) 245-253)

6. http://www.epilepsysociety.org.uk/AboutEpilepsy/Treatment/Medicationforchildren

7. Sabbagh S, et al. Impact of epilepsy characteristics and behavioral problems on school placement in children. Epilepsy & Behavior 9 (2006) 573-578

8. Guerrini R. et al. A randomized,phase III trial of adjunctive zonisamide in pediatric patients with partial epilepsy. Epilepsia, 2013 doi: 10.1111/epi.1223310. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224 - 2233.

9. Glauser T. et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. http://www.ilae.org/Visitors/Documents/Guidelines-epilepsia-12074-2013.pdf [Accessed April 2013]

10. Pugliatti M et al. Estimating the cost of epilepsy in Europe: A review with economic modeling. Epilepsia 2007: 48(12) 2224 – 2233.

Data di preparazione: luglio 2013

Codice incarico: Zonegran-UK2473c

SOURCE Eisai Europe Limited

Source: www.prnewswire.com

Social Status Affects Who We Choose To Believe

When it comes to news or political statements, the more powerful the speaker the more we are likely to believe them. Christie Nicholson reports For complete story, click here.

Theresa May diagnosed with diabetes

Theresa May diagnosed with diabetes
Home Secretary Theresa May reveals she has been diagnosed with Type 1 diabetes, but insists it will not affect her political career.

Saturday, July 27, 2013

China state media says 18 more detained in GSK probe

BEIJING (Reuters) - At least 18 more people have been detained in China in connection with a corruption scandal involving British drugmaker GlaxoSmithKline, state media reported, giving more details on an investigation that has rocked the company. China's state radio reported late on Friday on its website that police in the central city of Zhengzhou had "recently held, in accordance with the law, 18 GlaxoSmithKline (China) employees and some medical personnel". It provided no details of the detentions nor say exactly when they happened. ... Courtesy of Yahoo News

Guess Which Actress Was Spotted With a Lululemon Bag?

Can you guess which Southern belle walked out of her workout carrying a Lululemon bag?

Source

Friday, July 26, 2013

Philadelphia Twenty Years Later: Narrative and the Epidemic

Jonathan Demme and the creative team behind Philadelphia come to Columbia University to commemorate the 20th anniversary of the groundbreaking film

NEW YORK, July 26, 2013 /PRNewswire-USNewswire/ --

WHAT: The Program in Narrative Medicine at the Columbia University College of Physicians and Surgeons is hosting an event commemorating the 20^th anniversary of Philadelphia, the groundbreaking film directed by Jonathan Demme and starring Tom Hanks and Denzel Washington. "Philadelphia Twenty Years Later: Narrative and the Epidemic" will mark the milestone with events featuring the team directly involved in the project, as well as those who lived through the era and guided the narrative.

Released in 1993, Philadelphia was one of the first mainstream movies to address HIV/AIDS, homophobia, and discrimination. Tom Hanks and Bruce Springsteen each won an Academy Award for the film, and Ron Nyswaner was nominated for the Academy Award for Best Original Screenplay.

All proceeds from the event will benefit African Services Committee. AFC provides health, housing, legal, and social services to more than 10,000 newcomers to this country each year, focusing on HIV prevention, testing, care, and advocacy.

The program events will include:

The Making of Philadelphia: Paul Lazar will host a panel discussion with the creative team behind the film: Jonathan Demme (director), Ron Nyswaner (writer), Marc Platt (Sony Studios), and Ed Saxon (producer).

A Song for You: Alvin Ailey American Dance Theater will present a solo performance choreographed by Alvin Ailey for the Donny Hathaway 1972 version of the classic song.

Activism and Healthcare: Dr. Ron Bayer will host a discussion with Drs. Gerald Friedland and Michael Gottlieb, physician-activists at the forefront of the epidemic.

Artists, Representation, and Activism: Nellie Hermann will host writers Mark Doty and Marie Howe, both of whom explore themes of loss, beauty, care giving, and hope in their poetry and memoirs.

Two Men Talking: A performance created and performed by Paul Browde and Murray Nossel.

WHEN: Tuesday, November 12, 2013, 1pm ET to 9pm ET

WHERE: Alumni Auditorium, Columbia University Medical Center, 650 W. 168 St. (between Broadway and Ft. Washington Avenue), New York, NY 10032

TICKETS: $20 with Columbia University ID, $50 General Public
To purchase tickets in advance, visit http://www.narrativemedicine.org/philadelphia.html.

Program in Narrative Medicine

Through narrative training, the Program in Narrative Medicine helps healthcare professionals and educators to improve the effectiveness of care by developing the capacity for attention, reflection, representation, and affiliation with patients and colleagues. In addition to training faculty and medical students at the College of Physicians and Surgeons of Columbia University in narrative competency, the program offers a Master of Science degree in Narrative Medicine, intensive workshops, and inter-professional education programs designed to foster collaboration among the schools of the Columbia University Medical Center. For more information, visit www.narrativemedicine.org.

Contact:
Scott Alderman
1-212-305-9473
sma67@columbia.edu

SOURCE Program in Narrative Medicine

RELATED LINKS
http://www.narrativemedicine.org

Source: www.prnewswire.com

New CEO for Groote Schuur

Dr Bhavna Patel is the new CEO of Groote Schuur Hospital in Cape Town, the Western Cape health department said on Thursday. Source

Workout Motivation: Fitness Progress Video Footage

I decided to video my fitness progress instead of snapping pics this time… I figured it was better for documenting where I’m at and evaluating what I need to work on most. I like this method! You should try it, too. But too bad my hair is a hot mess. That’s what happens when I [...]

The post Workout Motivation: Fitness Progress Video Footage appeared first on Yum Yucky.

I decided to video my fitness progress instead of snapping pics this time…

I figured it was better for documenting where I’m at and evaluating what I need to work on most. I like this method! You should try it, too. But too bad my hair is a hot mess. That’s what happens when I kick my own ass in a training session. Check out the progress footage:

My thoughts? Definitely gotta take it to next level on arm and leg development. Go on and film your own progress for a little self-evaluation!

—-

√ Like me on Facebook

√ Follow me on Twitter

√ Subscribe to YumYucky on YouTube

The post Workout Motivation: Fitness Progress Video Footage appeared first on Yum Yucky.

You can get the whole story here.

Weight Loss For Women: Exercise and Diet Plan

Weight loss for women involves the same thing as it does for men. Eat fewer calories than your body burns on a daily basis and you will lose weight. The biggest mistake women make when trying to lose weight is dieting. Dieting is the act of temporarily adjusting ones eating habits to lose weight. This act has limited success in most cases. It is more constructive to make lifestyle changes. These changes are something you can live with on a daily basis instead of just for a few weeks or months at a time. Continue reading...

EU regulator finds no new safety issues with diabetes drugs

LONDON (Reuters) - European drugs regulators have found no new safety concerns with diabetes drugs known as GLP-1 and DPP-4 therapies after concluding a safety review of possible links to damage to the pancreas. The class of drugs - known as glucagon-like-peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors - includes Merck's $4 billion-a-year Januvia franchise, Novo Nordisk's Victoza, and Byetta and Onglyza from Bristol-Myers Squibb and AstraZeneca, among others. ... Credit of the story

Thursday, July 25, 2013

Calls for inquiry into NHS neglect

Calls for inquiry into NHS neglect
Calls are being made for an inquiry into Welsh NHS care standards and death rates following allegations an elderly patient suffered serious neglect at two south Wales hospitals.

U.S. HPV vaccination rates far from goal, officials say

U.S. HPV vaccination rates far from goal, officials say
By Yasmeen Abutaleb WASHINGTON (Reuters) - Only slightly more than half of U.S. girls aged 13 to 17 had been vaccinated against a virus that can cause cervical and other cancers last year, and a top U.S. health official said on Thursday that more must be done to bring the rate up to the long-term goal of 80 percent. The vaccination rate to protect against human papillomavirus (HPV) was 53.8 percent last year for teen-age girls, just marginally higher than the 53 percent rate a year earlier, the Centers for Disease Control and Prevention reported on Thursday. ...

Accountable Healthcare Holdings Corp Completes Oversubscribed Note Offering

BOCA RATON, Fla., July 25, 2013 /PRNewswire-iReach/ -- Accountable Healthcare Holdings Corp ("Accountable"), a provider of quality healthcare staffing solutions, today announced that it successfully completed its third capital raise since inception. The raise consisted of 5-year Notes with detachable equity warrants. Similar to the two private placement equity rounds completed in 2012, the Note raise was oversubscribed.

"We are very pleased with the results of our third private placement. We are well capitalized to execute our business plan which calls for making strategic healthcare staffing acquisitions and opening new 'de novo' locations", stated Robert J. Adamson, Chairman & CEO of Accountable Healthcare Holdings Corp. "We had a mix of repeat investors from our April and October 2012 equity rounds as well as bringing in several new investors."

Since inception, Accountable has opened 17 de novo offices in key markets. Accountable closed on the acquisition of HGI Healthcare, Inc. on July 8^th, the sixth acquisition since inception. Accountable expects to close its seventh acquisition shortly. In total, Accountable presently operates 29 offices throughout the US.

With over two centuries of combined experience between their Executive Management and Branch Teams, AHS is one of the fastest growing healthcare staffing companies in the U.S. With offices in Arizona, Colorado, Florida, Georgia, Illinois, Maryland, Missouri, New Jersey, New Mexico, North Carolina, Oklahoma, Oregon, Pennsylvania, Texas and Virginia, the Company's combined expertise began in the '70s when healthcare staffing was just gaining recognition and momentum. Today, AHS teams bring together market knowledge and insights that are reshaping service delivery with an emphasis on quality, integrity and clinical excellence.

To learn more about Accountable Healthcare Staffing, view the Company's web page at AHCStaff.com.

Media Contact: Robert J. Adamson, Accountable Healthcare Staffing, (561) 235-7811, RobertAdamson@AHCStaff.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE Accountable Healthcare Staffing

Source: www.prnewswire.com

How Many Calories Should I Consume to Lose Weight?

How Many Calories Should I Consume to Lose Weight?
The issue of losing weight by knowing your energy needs is not new and a common question often asked by dieters and weight watchers is how many calories should I consume to lose weight? The ...

Find Dependable Hypnotherapists Around

Roger offering hypnotherapy practice, hypnotherapists, clinical hypnotherapist, clinical hypnotherapy, quit smoking hypnosis, lose weight hypnosis, stop smoking, hypnotherapy, quit smoking, quit smoking scotland, Lose weight glasgow, Hypnotherapy scotland, Self confidence glasgow and weight loss...

For full post, click here.

Ginseng for cancer-related fatigue

A new study indicates that cancer patients and survivors who felt tired or sluggish reported feeling noticeably better after taking ginseng supplements. Source

Wednesday, July 24, 2013

Salmon with Mustard

Salmon with Mustard
Salmon is one of the best ways to get those hard-to-find omega-3 fatty acids into your Healthiest Way of Eating. Add mustard to the Quick Broiled salmon for a zesty, tasty treat! Prep and Cook Time: 10 minutes Serves 2 Ingredients: • 3/4 lb salmon fillet, cut in half • 2 tsp lemon ...

Save Yourself From the Strain: Moves to Help You Handle Your Heels

Don't let those chunky sandals take you out at the ankle. We all love a pair of high heels, but those stilettos and platform wedges can be taxing on your feet, ankles, and calves. Even your sense of balance gets worked walking around in pumps. With some simple strength training and stretching, you can feel confident and comfortable in those heels.

4 Tips For Kate, William - And All New Parents

4 Tips For Kate, William - And All New Parents
Choosing a name for their little prince is not the only worry for first-time parents, Kate and William. Like every new mom and dad their heads are probably spinning from all the things they must learn to take care of their beautiful new bundle of...

Can you spot what’s wrong with my grocery pics?

I didn’t buy this meat… …but when I passed by the meat section at the grocery store down the street, this slab of dead cow stuck out to me. The package say it’s “Good” and “Freshness Guaranteed”, but with that dead fly chillin’ by the package, I beg to differ. Is it gross, or what? [...]

The post Can you spot what’s wrong with my grocery pics? appeared first on Yum Yucky.

I didn’t buy this meat…

…but when I passed by the meat section at the grocery store down the street, this slab of dead cow stuck out to me. The package say it’s “Good” and “Freshness Guaranteed”, but with that dead fly chillin’ by the package, I beg to differ. Is it gross, or what? Definitely something wrong here. Where’s a food inspector when ya need him?

And next???

Shoppin’ at Trader Joe’s ya’ll. $42 worth of cereal. 16 boxes in all. You don’t even wanna know how much almond milk I have to buy to accommodate all this cereal.

I trek the 20 miles to TJ’s because they carry Envirokidz non-GMO cereal. I feel good about giving that to my child spawns instead of the chemically, GMO-enhanced Froot Loops ‘n such.

As you can see, I stock up big time. But what’s wrong with the situation and what’s downright disturbing? All that cereal won’t even last two weeks. The greedy mouths in my household are a perplexing mystery beyond explanation. It’s like the X-Files up in here.

Please commence to feeling sorry for me now. Dealing with dead flies and paying $42 for cereal is causing me to need your emotional support. Prop me up, ya’ll. Share in my pain.

—-

√ Like me on Facebook

√ Follow me on Twitter

√ Subscribe to YumYucky on YouTube

The post Can you spot what’s wrong with my grocery pics? appeared first on Yum Yucky.

Get the whole story here.

Doctors don't discuss dietary supplements

Doctors don't discuss dietary supplements
Doctors don't give patients enough information about vitamins, minerals, herbs and other dietary supplements, according to a new study.

GlaxoSmithKline CFO Interviewed on Q2 Results

LONDON, July 24, 2013 /PRNewswire/ --

Simon Dingemans, CFO, outlines the UK pharma group's Q2 performance, positive R&D pipeline news, as well as outlook and guidance for the rest of the year.

Dingemans also gives an update on his financial strategy plan, saying, "you could see in the second quarter the benefits of the restructuring programmes and some of the financial efficiencies we've identified really contributing to drive that leverage through the P&L and accelerate earnings per share of 4% faster than the sales growth of two per cent."

The video interviews and transcripts are available now on http://video.merchantcantos.com.

MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-(0)207-936-1352.

SOURCE GlaxoSmithKline

Source: www.prnewswire.com

Tuesday, July 23, 2013

Michael Kimball joins iMedX as Chief Revenue Officer

ATLANTA, July 24, 2013 /PRNewswire/ -- iMedX Inc. announced today that Michael Kimball would be joining its ranks as Chief Revenue Officer. The announcement comes on the heels of the company's recent appointment of Christopher Foley as its new Chief Executive Officer.

Michael brings over two decades of executive leadership experience in healthcare to iMedX. Most recently, he served as CEO of Diskriter, Inc., a Health Information Management and Medical Transcription solutions provider. Michael has also held senior leadership roles in Sales, Marketing and Operations with CBay Systems (now known as M*Modal), EDiX Corporation (acquired by Spheris, Inc.) and Kinetic Concepts Inc. Throughout his career, Michael's focus has been to establish a business model that promotes growth through organic sales and acquisitions with an emphasis on client retention, client relations and partner referrals. At iMedX, he will leverage his experience in providing integrated clinical documentation solutions and other related HIM services to hospitals, physician group practices, IDNs and clinics to support the company's rapid growth.

"Mike and I have worked together successfully in the past, and I anticipate even greater accomplishments in the future. iMedX has aggressive goals for expansion, and Mike's comprehensive industry knowledge and deep rooted client relationships provide us with a strategic advantage," said Christopher Foley. "I'm delighted to welcome Mike to the iMedX senior management team and I am excited about the great things we will accomplish with his leadership."

"I am absolutely thrilled to work alongside Chris again and join the iMedX team," said Michael. "The company is well-positioned for continued expansion and I'm looking forward to helping the team realize its full potential as a leader in integrated clinical documentation solutions."

About iMedX

iMedX is a leading healthcare technology company that develops software and solutions for hospitals and acute care facilities across the United States. The company is dedicated to improving the efficiency of physicians and the quality of patient care through robust clinical documentation. With an advanced technology platform, iMedX supports physician adoption of and transition to Electronic Health Record systems while mitigating provider productivity loss and encouraging adherence to health information best practices. Founded in 2002 and headquartered in Atlanta, Georgia, the company has satellite offices nationwide and in India. For more information, please visit www.imedx.com.

SOURCE iMedX

Cut Your Calorie Intake By Eating Slower

“Nature will castigate those who don’t masticate” –Horace Fletcher “Drink your food and chew your water” –Paul Chek These two phrases come from different nutritionists, whose view on the importance of chewing your food ( a lot) matters – a lot. But what does it mean? What can you gain, or lose, from more thoroughly [...]

The post Cut Your Calorie Intake By Eating Slower appeared first on BuiltLean.com.

“Nature will castigate those who don’t masticate”
–Horace Fletcher

“Drink your food and chew your water”
–Paul Chek

These two phrases come from different nutritionists, whose view on the importance of chewing your food ( a lot) matters – a lot.

But what does it mean? What can you gain, or lose, from more thoroughly chewing food? Can it really help you eat less and cut your calories down as much as many claim?

In brief, aside from some special cases like nuts, chewing more should help you cut calorie intake. Chewing more has many effects on feeding behavior, appetite, and digestion – some good and some questionable, depending on your goals.

Why You Should Chew More & Eat Slower

In one study, participants were fed small (5 grams) or large (15 grams) mouthfuls of chocolate custard, and allowed to chew for 3 or 9 seconds prior to swallowing¹. Then, for the next 30 minutes they were allowed to consume as much or as little chocolate custard as they wanted. The results showed that significantly less chocolate custard was eaten if they were initially fed small bites and/or allowed to chew it more prior to swallowing. In fact, comparing the two extreme conditions (small bite size & longer chew time vs. large bite size & shorter chew time), the difference in subsequent intake amounted to 294 vs. 447 kcal – that’s a 52% increase!

Similarly, another study showed that subjects assigned to chew their food 40 times ate 11.9% less than those assigned to chewing it 15 times².

Collectively, these data suggest that taking the time to enjoy your food, eat slowly & savor it, can cause you to eat less. Eating slower may be particularly important because it takes our brain and stomach about 20 minutes to register feelings of fullness.

The Curious Case Of Nuts

Nuts are a phenomenally complex food, consisting of a blend of proteins, fats, carbs, and fibers, all packaged tightly into small calorie-dense bundles. And the release of those calories may depend more on how well you chew than on anything else.

In one study, participants were given roughly 2 ounces of almonds per day and instructed to chew 10, 25, or 40 times³. The results showed that significantly less fat was absorbed when the almonds were chewed only 10 times. The subjects who chewed more reported feeling fuller and less hungry, but this may be due as well to the fact that they absorbed more calories, not only that they chewed their food more.

These findings were confirmed in another study, albeit indirectly. In this one, subjects were given either peanuts, peanut butter, or peanut oil, and fat absorption was subsequently monitored⁴. The peanuts most closely resembled the 10-chew condition in the almond study, peanut butter the 25-chew, and peanut oil the 40-chew condition. And the results were similar – peanut ingestion was associated with significantly less, and peanut oil significantly more absorption of the fat in peanuts. What this study suggests it that when it comes to nuts, sticking to whole nuts may result in less calorie absorption than nut butters and nut oils. While this is not a direct, chew vs less chew scenario, it does relate the idea that in either case, chewing seems to be our friend when it comes to less caloric intake.

Chewing More & Eating Slower Can Cut Your Calorie Intake

Based on the research examine here, when eating a mixed meal, smaller bites and longer chewing times may result in less hunger and eating less food overall. Chewing more not only allows for more absorbtion, but also seems to signal to the body that you have eaten enough, allowing your brain (which is slightly behind your stomach’s reaction to this) to register a feeling of fullness.

The post Cut Your Calorie Intake By Eating Slower appeared first on BuiltLean.com.

Are Smaller Restaurants Healthier? Not If You're Trying to Lose Weight, Says Study

plate Do you really make the best choices when you dine out? Those of us who try to eat healthy often do so by avoiding large chain restaurants. Not only is the fat and calorie content of fast food very high, but many times the food just doesn't taste good. So, if you're like me, you prefer to spend your money at locally owned bistros and cafes where the food at least looks like it's healthier. But is it? If weight loss is your goal, it might not be.

...

Read Full Post

You can get the whole story here.

RKNet Studio Receives NJBIN Award for Innovation and Excellence at...

RKNet Studio, the producer of Cognitions Bridge suite of brain fitness and cognitive skills development mobile apps, was selected as an award-winning company by the New Jersey Business Incubation...

(PRWeb July 23, 2013)

Read the full story at http://www.prweb.com/releases/2013/7/prweb10940772.htm

Teen self-consciousness is biological

Teen self-consciousness is biological
Teenage self-consciousness is biological and just anticipating being watched can trigger emotional response, researchers say.

Monday, July 22, 2013

Federal judge halts new North Dakota abortion law, for now

By Brendan O'Brien (Reuters) - A federal judge on Monday temporarily blocked North Dakota's new abortion law, the most restrictive in the country because it prohibits ending a pregnancy once a fetal heartbeat can be detected, which can be as early as six weeks after conception. Banning abortions as early as six weeks, or before fetal viability between 24 and 26 weeks of gestation, would bar nearly 90 percent of the abortions performed at the Red River Women's Clinic, the state's only abortion clinic, said its director, Tammi Kromenaker. U.S. ...

Rituals make the cake taste better

New research suggests that birthday celebration rituals not only make the experience more memorable, but might also improve the taste of the cake. You can get the whole story here.

Isis Pharma drug reduces blood fat by 64 pct in mid-stage study

(Reuters) - Isis Pharmaceuticals Inc said its experimental drug reduced the level of triglycerides, a type of fat in the blood that increases the risk of heart diseases, by up to 64 percent in a mid-stage trial. Shares of the company rose 2.4 percent to $31.80 in light trading before the bell. Isis said the drug, codenamed ISIS-APOCIIIRx, was being tested in patients with high to severely elevated triglyceride levels, who were taking another drug to reduce blood fat. Isis's drug raised the level of 'good' cholesterol in the blood by up to 52 percent. ... For full post, click here.

Vegan Uncensored: Why Vegans Need More Non-Vegans in Their Lives

There have been several times in the past few years when something has happened on the provincial (I'm in Canada) or national political scene, driven by public opinion, that has completely taken me by surprise. This is not because I don't follow the news, or because I am completely tuned out. It's not because it's something new for me to disagree with a lot of mainstream attitudes. However, I have started to realize that increasingly in my life I have been surrounding myself with people who have the same kind of values as I have, and this makes me think about the world in a certain way

Image courtesy of artur84 / FreeDigitalPhotos.net

There have been several times in the past few years when something has happened on the provincial (I’m in Canada) or national political scene, driven by public opinion, that has completely taken me by surprise. This is not because I don’t follow the news, or because I am completely tuned out. It’s not because it’s something new for me to disagree with a lot of mainstream attitudes.

However, I have started to realize that increasingly in my life I have been surrounding myself with people who have the same kind of values as I have, and this makes me think about the world in a certain way. I don’t think it’s unusual or surprising to surround oneself with kindred spirits; most of us want to spend time with like-minded people. With social media sites just for vegans, and even vegan love-match sites, it’s easier than ever before to connect with other vegans in this non-vegan world. Great, right? Who wants to argue or feel defensive, or spend a lot of time with people they feel just might be living on a different planet?

But in reality, taken too far, that’s a very dangerous thing for the vegan movement. It’s important for vegans to have a community of people to support them – one of the most enjoyable events in my month is the vegan potlucks where people in my community come together to enjoy delicious vegan food. It’s a chance to connect with people I feel I can be open and honest with. Similarly, most of my closest friends are vegans and people who have similar world views to me. This all makes sense, but I have started to realize that I NEED more non-vegans in my life!

In order to start and have – and get good at starting and having – constructive conversations about veganism and compassionate living, we need to reach outside our circles and face those conversations with courage and grace. Though we need vegan supports in our lives, it’s important to push ourselves to step outside our own comfort zones – not just by hanging out with non-vegans, but by forcing ourselves to have those conversations. This will not only allow others to hear what we have to say about the reasons for being vegan; it will allow us to maintain a realistic view of the world, and to hopefully find more compassion for “the other side.”

Read the full article.

Related Contents
http://mediawiki.spsnome.cz/index.php/Do_You_Really_Want_Help_On_All_Natural_Weight_Loss_Pills
http://kingdomofjehovah.com/read_blog/449/the-facts-concerning-effective-slimming-supplements
http://www.iamsport.org/pg/blog/ponysten/read/17124982/why-finding-the-right-diet-plan-is-vital

Acquisition of Devices, Methods and Intellectual Property Support Leadership Position in Regenerative Therapies

AUSTIN, Texas, July 22, 2013 /PRNewswire/ -- On Wednesday, July 17^th, Celling Biosciences made an asset acquisition of devices, proprietary methods and intellectual property from Orogen Biosciences. Orogen, based out of Sarasota, Florida, was an early innovator in processing platelet rich plasma (PRP) and concentrating growth factors and cytokines to optimize the most effective and efficient methods for providing therapeutic treatments with a patient's own tissue. With this acquisition, Celling is furthering its position as a leader of point of care, autologous cell therapy.

Celling is focused on the three pillars of regenerative medicine (cells, substrates, and signals) known to enhance the environment for tissue repair, regeneration, and revascularization. The devices (OPC and ACE) and methods from Orogen provide physicians with access to a patient's own growth factors and proteins to support the healing cascade. There is a growing body of evidence in the literature of the role growth factors play in optimizing the healing in multiple pathologies across medicine. The OPC device allows physicians to process autologous plasma at the point of care to deliver concentrated growth factors when compared to currently marketed options. The ACE device is a unique technology that produces an enriched preparation of growth factors without the presence of white blood cells, red blood cells or platelets.

Additionally, Celling has acquired methods and devices for delivering allogeneic products to the veterinary market. Based on the short and long term success of these products in treating horses and canines in soft tissue repair, Celling will be well positioned to penetrate the veterinary market which is leading human efforts into the emerging market of regenerative medicine.

Celling has begun the process of transitioning Orogen revenues, opening a Florida office and launching devices to the market within the next quarter. "We believe this is a unique opportunity for Celling to keep building our product and services portfolio in the autologous space. We continue to expand our registered nurse service model across the country anticipating the orchestrated event in cell therapy between physicians and technology providers. This acquisition is another step in adding sophistication to the process," says Kevin Dunworth, CEO and Founder of Celling Biosciences. We had a number of companies approach us about acquiring Orogen's intellectual property but we were waiting on the right fit both culturally and philosophically based on who we believed to be a leader in cell therapy innovation. "We are extremely excited about this development and are confident that Celling Biosciences has the vision to create significant value in the regenerative medicine space," says Ryan Brandt, President of Orogen.

About Celling Biosciences
Celling Biosciences is an Austin, Texas based company working closely with world leaders in academia, medicine, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine. Celling's product-offering focuses on autologous cell therapy and the devices and services that compliment these procedures. For more information please visit: www.cellingbiosciences.com.

Troy Wilford
twilford@cellingbiosciences.com

SOURCE Celling Biosciences

Source: www.prnewswire.com

Sunday, July 21, 2013

VIDEO: Free health checks 'will save lives'

Hundreds of lives could be saved if the NHS and local authorities in England did more to encourage people to take up free health checks, the health secretary has said. Here is the full post.

Saturday, July 20, 2013

Fatal Indian school meal contained pesticide, police confirms

PATNA, India (Reuters) - An initial forensic report has confirmed that the free school lunch that killed 23 children this week in India's eastern state of Bihar was contaminated with a pesticide, a senior police official said on Saturday. The children fell ill within minutes of eating a meal of rice and potato curry in their one-room school on Tuesday, vomiting and convulsing with agonizing stomach cramps. The deaths sparked protests in Bihar. The lunch was part of India's Mid-Day Meal Scheme that covers 120 million children and aims to tackle malnutrition and encourage school attendance. ...

Diane Walder, MD Called “Miami’s Skincare Queen” by Travel and Leisure...

Miami Dermatologist Featured in Article on Miami’s Latest Health and Mood Boosting Trends

(PRWeb July 20, 2013)

Read the full story at http://www.prweb.com/releases/2013/7/prweb10941841.htm

Friday, July 19, 2013

Childhood abuse increases suicide risk

Childhood abuse increases suicide risk
Drug users with a history of severe childhood abuse may have an increased risk for suicide, a new study says.

Feature Interview with Sharon Palmer: Go Plant-Power! Challenge starts August 5

Feature Interview with Sharon Palmer: Go Plant-Power! Challenge starts August 5
Summer is a great time to go plant-based, and if you need a push in the right direction, look no further! Sharon Palmer, aka The Plant-Powered Dietitian, will launch her second 14-Day Go Plant Power! Challenge on Monday, August 5th. We had a chance to chat with Sharon recently about the challenge, how it is different from other vegan kickstarts, why people should do it, and lots of other details...so read on!

Summer is a great time to go plant-based, and if you need a push in the right direction, look no further! Sharon Palmer, aka The Plant-Powered Dietitian, will launch her second 14-Day Go Plant Power! Challenge on Monday, August 5th. We had a chance to chat with Sharon recently about the challenge, how it is different from other vegan kickstarts, why people should do it, and lots of other details…so read on!

�

photo courtesy of Sharon Palmer

Vegan Mainstream (VM): Why did you decide to host this challenge?

Sharon Palmer (SP): I believe that people can gain remarkable health benefits by taking on a more plant-based diet, no matter where they are. If they’re eating meat three times a day, perhaps they could cut it back to once a day. Maybe they can try Meatless Monday. And if you’re a vegetarian, perhaps you’d like to try going vegan for 14 days, just to see how it feels. It gives you a unique opportunity to give something a try and see if it’s for you. When I did research for my book a couple of years ago, I had been a vegetarian for quite some time. But I decided to try a 30-day vegan challenge, because I wanted to know what it felt like to be a vegan–how difficult it would be, how my body would react. As a health expert, I felt that I needed to understand this first hand. The experience was so positive, that I decided to stick with it!

VM: How is this challenge different from some of the other vegan kickstarts or challenges out there?

SP: My challenge is more flexible. I believe that everyone can benefit from a plant-based diet and can do it! While many may not consider a vegan challenge right from the start, they should be able to start with cutting back on meat and eating more whole plant-based foods. After all, Americans eat meat at three times the global rate. They can feel so good about making a positive change, and it can become a new lifestyle for them. Can you imagine the impact on health–and the environment and animal welfare–if everyone in the US cut their meat intake by half? I have had readers of my book make tremendous, positive impacts on their health by taking on this lifestyle. I’ve had die-hard carnivores cut back on red meat to once a month and discontinue statins because their blood levels were so positive. After they have made these more gradual changes, they may consider further progressing their diet towards a vegan lifestyle.

VM: Does it cost anything for people to get involved?

SP: No, this is a free service I’m providing to people to help them kickstart their health.

VM: What does being involved in the challenge entail for participants?

SP: All they have to do is sign up on the Go Plant Power FB page to get the daily alerts and instructions for the challenge. We even have lots of prizes for those that get involved. We will provide education and daily tips and recipes.

VM: What benefits do you think people who are participating in and really sticking to the challenge will see?

SP: I have people tell me that they feel better within a couple of days. People can also lose a few pounds, which can help them get more enthusiastic about a healthy eating pattern for life. People also gain a new understanding for healthy, whole plant foods, such as ancient whole grains, nuts, seeds, beans, lentils, vegetables, and fruits.

VM: Who is the ideal candidate to try this challenge?

SP: Anyone who would like to take their diet to the next plant-powered level. Whether you’d like to go vegetarian for two weeks, give up red meat for two weeks, or even eat two vegetarian meals per week, this challenge is for you. On the first day of the challenge, I ask you to consider your goals for health and sustainable living and then make your decision and set a goal. Then every day I will guide you to eating more whole plant-based foods.

VM: How many people are you hoping to reach?

SP: I would really like to reach a few thousand people on this challenge.

VM: Why did you choose a 2-week challenge instead of longer, or shorter?

SP: I believe that two weeks can really give you the chance to learn about a new lifestyle. It gives you time to see if it’s right for you, and whether you have gained benefits from it.

VM: Why should people try this?

SP: Hundreds of studies point to one thing: a plant-based diet–a diet that focuses on plants, not animals–is the healthiest diet on the planet. It’s not only rich in all of the good stuff–fiber, vitamins, minerals, phyochemicals; it’s low in all of the bad stuff: cholesterol, saturated fat, toxins. Most traditional, cultural diets are plant-based–whether you’re in Peru or Asia. We have strayed away from our healthy plant-based diets to the typical American diet, which we know is linked with poor health–death, obesity, disease.

VM: What are the best resources you can recommend or tips you can offer for people who are just starting on a vegan diet?

SP: I believe my book is a great resource, it tells you how to do it healthfully. There are also a number of brilliant books written on the subject by people like Neal Barnard, Virginia Messina and Reed Mangels. The most important thing is to develop a cooking style that can support this diet. You have to have healthy, plant-based foods that will meet your nutritional needs available. You can’t just wing it.

Interested? Check out the Go Plant-Power! Challenge Facebook Page and sign up today!

You Might Also Like
http://www.azfreelyrics.com/read_blog/39327/find-out-the-amazing-insight-about-safe-slimming-pills
http://amrilulanah.xanga.com/773397429/how-do-i-cut-weight/
http://www.fencepost.co.za/index.php?do=/blog/2264/the-dirty-truth-regarding-slimming-products/
http://www.fizzlive.com/member/329936/blog/view/457670/